Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase

Journal of Clinical Microbiology

Volumn 37, Issue 7, 1999, Pages 2291-2296

  Schuurman, Rob ^a   Demeter, Lisa ^b   Reichelderfer, Patricia ^c   Tijnagel, Jolanda ^a   De Groot, Tom ^a   Boucher, Charles ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ARTICLE; DIAGNOSTIC ACCURACY; DNA SEQUENCE; DRUG RESISTANCE; ENZYME ISOLATION; GENETIC HETEROGENEITY; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; VIRUS RESISTANCE;

EID: 0033037358     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.37.7.2291-2296.1999     Document Type: Article

References (19)

1. Baxter, J. D., D. L. Mayers, D. N. Wentworth, J. D. Neaton, T. C. Merigan, and the CPCRA Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. 1999. A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretorviral therapy, abstr. LB 8. In Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections.
2. Boucher, C. A. B., W. Keulen, T. van Bommel, M. Nijhuis, D. de Jong, M. D. de Jong, P. Schipper, and N. K. T. Back. 1996. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob. Agents Chemother. 40:2404-2409.
3. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
4. Demeter, L. M., R. D'Aquila, O. Weislow, E. Lorenzo, A. Erice, J. Filzgibbon, R. Shafer, D. Richman, T. M. Howard, Y. Zhao, E. Fisher, D. Huang, D. Mayers, S. Sylvester, M. Arens, K. Sannerud, S. Rasheed, V. Johnson, D. Kuritzkes, P. Reichelderfer, A. Japour, ACTG Sequencing Working Group, and AIDS Clinical Trials Group. 1998. Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. J. Virol. Methods 75:93-104.
5. Durant, J., P. Clevenbergh, P. Halfon, P. Delguidice, S. Porsin, P. Simonet, N. Montagne, E. Dohin, J. M. Schapiro, C. Boucher, and P. Dellamonica. Improving HIV therapy with drug resistance genotyping: The Viradapt Study. Lancet, in press.
6. Japour, A. J., D. L. Mayers, V. A. Johnson, D. R. Kuritzkes, L. A. Becket, J.-M. Arduino, J. Lane, R. J. Black, P. S. Reichelderfer, R. T. D'Aquila, Clyde S. Crumpacker, The RV-43 Study Group, and The AIDS Clinical Trials Group Virology Committee Resistance Working Group. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37:1095-1101.
7. Kaye, S., C. Loveday, and R. S. Tedder. 1992. A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine. J. Med. Virol. 37:241-246.
8. Kemp, S. D., A. Kohli, and B. A. Larder. 1995. Genotypic characterization of an HIV-1 mutant co-resistant to AZT and 3TC. J. Acquired Immune Defic. Syndr. 10:S25. (Abstract.)
9. Kozal, M. J., N. Shah, N. Shen, R. Yang, R. Fucini, T. C. Merigan, D. D. Richman, D. Morris, E. Hubbell, M. Chee, and T. R. Gingeras. 1996. Extensive polymorphism observed in HIV-1 clade B protease gene using highdensity oligonucleotide arrays. Nat. Med. 2:753-759.
10. Kuritzkes, D. R., J. B. Quinn, D. L. Shugarts, A. Griffin, M. Bakhtiari, D. Poticha, J. J. Eron, M. A. Fallon, and M. Rubin. 1996. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 10:975-981.
11. Leigh Brown, A. J., and D. D. Richman. 1997. HIV-1: gambling on the evolution of drug resistance? Nat. Med. 3:268-271.
12. Nijhuis, M., C. A. B. Boucher, P. Schipper, T. Leitner, R. Schuurman, and J. Albert. 1998. Stochastic processes strongly influence HIV-1 evolution during suboptimal protease inhibitor therapy. Proc. Natl. Acad. Sci. USA 95:14441-14446.
13. Nijhuis, M., R. Schuurman, and C. A. B. Boucher. 1997. Homologous recombination for rapid phenotyping of HIV. Curr. Opin. Infect. Dis. 10:475-479.
14. Perrin, L., and A. Telenti. 1998. HIV treatment failure: testing for HIV resistance in clinical practice. Science 280:1871-1873.
15. Rosenblum, B. B., L. G. Lee, S. L. Spurgeon, S. H. Khan, S. M. Menchen, C. R. Heiner, and S. M. Chen. 1997. New dye-labeled terminators for improved DNA sequencing patterns. Nucleic Acids Res. 25:4500-4504.
16. Schinazi, R. F., B. A. Larder, and J. W. Mellors. 1997. Mutations in retroviral genes associated with drug resistance. Int. Antiviral News 5:129.
17. Schuurman, R. 1997. State of the art of genotypic HIV-1 drug resistance. Curr. Opin. Infect. Dis. 10:480-484.
18. Schuurman, R., M. Nijhuis, R. van Leeuwen, P. Schipper, D. de Jong, P. Collis, S. A. Danner, J. Mulder, C. Loveday, C. Christopherson, S. Kwok, J. Sninsky, and C. A. B. Boucher. 1995. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171:1411-1419.
19. Syvanen, A. C., K. Aalto-Setala, L. Harju, K. Kontula, and H. Soderlund. 1990. A primer-guided nucleotide incorporation assay in the genotyping of apolipoprotein E. Genomics 8:684-692.